Objectives: Historically, arthroplasty in systemic lupus erythematosus (SLE) patients has been less successful than for patients with osteoarthritis (OA). It is not known if SLE remains an independent risk factor for poor arthroplasty outcomes or if other factors, such as avascular necrosis (AVN), continue to play a role. Methods: A case-control study using data from a single-institution arthroplasty registry compared SLE total hip arthroplasty (THA) and total knee arthroplasty (TKA) with OA controls matched by age, gender and presence of AVN. Baseline, two-year administrative and self-report data, and diagnosis leading to arthroplasty were evaluated. Results: A total of 54 primary SLE THA and 45 primary SLE TKA were identified from May 2007 through June 2011. AVN was present in 32% of SLE THA and no TKA. SLE THA had worse preoperative WOMAC pain (42.5 vs. 52.7; p ¼ 0.01) and function (38.8 vs. 48.0; p ¼ 0.05) compared with OA. However, at two years there was no difference in WOMAC pain (91.1 vs. 92.1; p ¼ 0.77) or WOMAC function (86.4 vs. 90.8; p ¼ 0.28). SLE TKA were similar to OA in both preoperative pain (42.6 vs. 48.4; p ¼ 0.14) and function (42.1 vs. 46.8; p ¼ 0.30) and two-year pain (85.7 vs. 88.6; p ¼ 0.50) and function (83.7 vs. 85.1; p ¼ 0.23). Compared to OA, SLE THA and TKA patients had more renal failure (14% vs. 1%; p ¼ 0.007) and hypertension (52% vs. 29%; p ¼ 0.009). In a multivariate linear regression, SLE was not predictive of either poor pain or poor function. Conclusions: While SLE patients have more comorbidities than OA, and SLE THA have worse preoperative pain and function compared with OA controls, SLE was not an independent risk factor for poor short-term pain or function after either hip or knee arthroplasty. Lupus (2015) 24, 900-908.
Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. While arthritis is the most common manifestation of SLE and is present in more than 90% of patients, the primary arthritis in SLE is not typically described as destructive or erosive. 1 Nonetheless, patients with SLE undergo joint arthroplasty; rates of arthroplasty in SLE patients have been increasing. 2 Historically, while 50% of total hip arthroplasty (THA) in patients with SLE have been for avascular necrosis (AVN), a common concurrent condition associated with corticosteroid therapy, recent reports note lower rates of arthroplasty for AVN. 3, 4 Other reasons reported for joint replacement in patients with SLE are rheumatoid arthritis overlap syndrome, infection, fracture, and osteoarthritis (OA). 4 SLE patients have been reported to have THA results similar to patients with inflammatory arthritis, but to have worse outcomes compared to patients with OA. 5, 6 Older literature suggests poorer outcomes after THA in SLE patients with AVN, 7 although SLE patients have fewer revision surgeries when compared with other patients undergoing THA for AVN. 8 For SLE patients with AVN of the knee, poorer clinical outcomes are reported after total knee arthroplasty (TKA) when compared to TKA patients with other etiologies for AVN. 9 However, a recent retrospective study of SLE patients undergoing THA both for AVN and OA does not report a difference in outcomes when these patients are compared to those without SLE who have AVN. 10 Over the past decades there have been tremendous advances in the medical care of SLE patients, specifically a decreased reliance on corticosteroids and an increased use of steroid-sparing medications. In addition, there have been significant improvements both in anesthesia and arthroplasty techniques. Moreover, as fewer patients with SLE undergo arthroplasty for AVN, quality of life outcomes after arthroplasty may differ from the outcomes reported for AVN. We hypothesize that SLE itself is no longer an independent risk factor for poor pain and function after arthroplasty. The objective of this study is to evaluate SLE patients undergoing THA and TKA and determine their pain and function outcomes using prospectively gathered patient-reported quality of life outcome measures, and to compare them to controls matched for confounders such as age, gender, and the presence of AVN.
Methods
Patients were eligible for this study if they had a primary THA or TKA enrolled in the Hospital for Special Surgery (HSS) Total Joint Replacement Registry between May 2007 and June 2011. This is a prospective, single-institution arthroplasty registry that enrolled approximately 80% of all patients and contains administrative data as well as preoperative and two-year self-report data.
Patients with International Classification of Diseases, ninth revision (ICD-9) code for SLE (710.0) were identified. Charts were reviewed, and the diagnosis of SLE was validated if the patient had three out of 11 American College of Rheumatology (ACR) SLE criteria documented, 11, 12 the patient was on immunosuppressant therapy other than prednisone, or if the diagnosis of SLE was independently confirmed by his or her consulting rheumatologist. This method of case validation was chosen because, as a tertiary referral center, most SLE cases were from other centers. We therefore did not have access to detailed rheumatology records. It has been shown that rheumatologist confirmation increases the accuracy of the diagnosis. 13 Diagnosis codes in selected populations have a high positive-predictive value for SLE as do diagnoses made on more than one encounter. 14 In addition, the accuracy of the diagnosis of rheumatoid arthritis based on ICD-9 code was shown to increase if evidence of disease-modifying antirheumatic drug (DMARD) use was also obtained and included in the diagnostic algorithm. 15 Therefore, after identification of the ICD-9 code of SLE, we included documentation of at least three SLE ACR criteria, use of immunosuppressive medications, and diagnosis by a rheumatologist to increase the specificity of the diagnosis of SLE. Given this limitation, the patients in the study cohort will be referred to as SLE/likely SLE.
Two OA cases were matched to each SLE/likely SLE case on age AE 2.5 years, sex, procedure type and presence of AVN. Matching was implemented to reduce confounding, and it allowed us to assess the relationship between SLE and clinical outcomes, having already taken these confounding factors into account. AVN was confirmed in cases and controls if present on the preoperative radiograph or magnetic resonance imaging (MRI) or if AVN was identified on the post-surgical pathology specimen report. For pathologic specimens, the Ficat and Arlet classification scheme was used to classify the different stages of AVN. 16 OA was confirmed by the preoperative radiograph or the pathology specimen report.
All cases and controls with an ICD-9 code for other autoimmune diseases, inflammatory arthritis, or fracture were excluded.
All registry patients completed baseline questionnaires regarding demographic and self-reported health, function and quality of life outcomes preoperatively and again at two years. These included the HSS Total Hip or Knee Expectations Survey (at baseline only), which is a 19-item questionnaire covering different aspects of surgical recovery including pain relief and ability to complete different activities. Scores are reported on a scale of 1-100; higher scores indicate higher expectations. 17, 18 The Western Ontario McMaster University Osteoarthritis (WOMAC) survey is a lower extremity-specific patient-reported measure used to assess arthritis pain, stiffness and function; lower scores indicate worse status. The survey has been validated for total hip and total knee arthroplasty and is derived from the Hip Disability and Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) surveys, which are completed by patients at baseline and two years. 19 A difference of 10 points is considered a clinically meaningful change. 20 The Short Form-36 (SF-36) Physical Component Summary Score (PCS) and Mental Component Summary Score (MCS) are two composite subscales of the generic validated patient-reported measure of general health and well-being, with higher scores indicating better status. A difference of five points is considered clinically meaningful. 21 The Euro-Qol 5D (EQ-5D) assesses the subjective value placed on one's health, with a score of 1 indicating perfect health and zero indicating death. 22 The Lower Extremity Activity Scale (LEAS) is a validated scale composed of 12 questions assessing different levels of activity. 23 Using ICD-9 codes, the Elixhauser Comorbidity Measures were obtained from the hospital administrative database for each patient.
Analysis
Total knee and total hip replacements were analyzed separately. Variables used for matching were compared between the cases and controls to evaluate the quality of matching. Descriptive statistics were generated for patient demographics, selfreported outcomes, and comorbidities. Characteristics in the SLE cases and OA controls were compared using Chi-square or Fisher exact tests for categorical variables and two-sample Student's t-test for continuous variables. Multiple linear regression models were performed comparing outcomes at two years between SLE cases and OA controls. The models included main effects for SLE and OA, preoperative pain or function, and patient characteristics that were found to be significant in univariate analyses. Prior to performing the multivariate analysis, we also examined the relationship between SLE/likely SLE and clinical outcomes using simple linear regression (unadjusted) and the matched cohort. No statistically significant relationship between SLE/likely SLE and outcomes was found in either unadjusted or adjusted analysis; and therefore, only results from the multivariate analyses were reported. Matching on age AE 2.5 years, sex, procedure type and presence of AVN allowed us to assess the relationship between SLE/likely SLE and clinical outcomes, having already taken these confounding factors into account. In order to minimize residual confounding, matching variables that were not evenly distributed between the two groups (i.e. the presence of AVN) were included in the models to account for the imbalance between groups. Differences between patients with and without two-year data were evaluated to identify potential biases and were not found to be significant. If patients had more than one surgery, the latest procedure with follow-up data was included. Multicollinearity diagnostics were conducted for each analysis by assessing the variance inflation factor (VIF) for each independent variable. No VIF values exceeded 2.5, and therefore no significant multicollinearity was presented among the independent variables.
All analyses were performed using SAS for Windows 9.3 (Cary, NC). All tests were two sided with a critical p value of 0.05 regarded as statistically significant.
This study was approved by our institutional ethics review board. Informed consent was obtained from all individual participants included in this study.
Results
A total of 183 THA and TKA patients with ICD-9 code 710.0 (SLE) were identified, and the diagnosis was validated in 99 patients after chart review. Fifty-four of the SLE/likely SLE patients had undergone primary THA, of whom 17 had evidence of AVN (32%). In contrast, of the 45 SLE patients who had undergone TKA, none had AVN. These 99 cases were matched to 198 OA controls ( Table 1 ). Preoperative self-report data were available for 60/99 SLE cases (61%) and 135/198 OA (68%); two-year self-report data were available for 45/99 SLE (46%) and 103/198 OA (52%). Although questionnaire response rate was poor at two years, there was no difference between patients with or without responses in age (58.0 years vs. 57.8 years; p value ¼ 0.90) or body mass index (BMI) (28.7 vs. 29.5; p value ¼ 0.38). Patients with higher education levels were more likely to complete the follow-up surveys. There was no difference in the expectations score between those with or without two-year responses (81.6 vs. 85.6, p value ¼ 0.14).
THA
Among THA ( Table 3 ). There was no significant difference in EQ 5D scores preoperatively (0.6 vs. 0.6; p value ¼ 0.30) and at two years postoperatively (0.8 vs. 0.9; p value ¼ 0.60). Baseline activity levels measured with the LEAS were comparable at baseline (8.4 (SLE) vs. 9.4 (OA); p value ¼ 0.14) and increased at two years (10.4 (SLE) vs. 11.0; p value ¼ 0.42) with no significant differences between groups.
Multivariate linear regression
For THA, a multivariate linear regression (Table 4 ) was performed to determine predictors of pain and function at two years after controlling for baseline SF-36 MCS, PCS, AVN status, and WOMAC pain or function. Although a matching variable, AVN status was included in the regression model to account for the slight imbalance between groups. (Table 5 ) performed to determine predictors of poor pain and function outcomes controlling for SF-36 MCS and PCS and baseline pain or function, SLE was not an independent predictor of poor WOMAC pain (point estimate 0.69; 95% CI -7.86, 9.24; p value ¼ 0.87) or function (point estimate 3.11; 95%CI À5.18, 11.4; p value ¼ 0.46) at two years.
Discussion
In this analysis, after controlling for important potential confounders, the diagnosis of SLE was not associated with poor pain or function after THA or TKA. Surprisingly, there were multiple differences between SLE/likely SLE THA patients and SLE/likely SLE TKA patients at the preoperative baseline evaluation. SLE/likely SLE TKA patients were older, had higher BMIs and had no evidence of AVN, in contrast with the younger THA patients, of whom 32% had AVN. The low overall prevalence of AVN in these patients may reflect less reliance on high-dose corticosteroids for disease control compared with earlier SLE cohorts. In addition, prior to surgery, SLE/likely SLE patients undergoing THA had worse pain and function, quality of life, and lower activity levels than OA patients, while SLE/likely SLE patients undergoing TKA were similar to the OA patients in these measures. However, there was little difference in preoperative pain and function between SLE/likely SLE patients undergoing TKA when compared with SLE/likely SLE patients undergoing THA. Interestingly, expectations of arthroplasty outcomes were comparable for all groups, despite the increased burden of comorbidities in the SLE/likely SLE patients.
At two years, pain and function both for THA and TKA were comparable between SLE/likely SLE patients and OA patients. While previous series have reported quality of life outcomes for THA in SLE, 5,7 this has not been reported for SLE TKA patients, in whom reports have focused on infection and revision. 9, 24 The striking differences between our TKA and THA cohorts in age, BMI, and prevalence of AVN were consistent with our previous large populationbased study, which reported that SLE undergoing TKA were almost 10 years older than SLE THA. 2 Only 17% of the overall SLE arthroplasty cases had AVN, similar to the low prevalence of AVN reported in our population-based study, where 24% of SLE THA cases were performed for AVN. 2 However, as neither comorbidities nor medication use were significantly different between the SLE/likely SLE THA and TKA in this cohort, These observations need to be considered in the face of specific limitations. The diagnosis of SLE was validated via chart review, not patient interview and examination, and, therefore, there could have been potential misclassification. However, use of ICD-9 codes on multiple visits, expert opinion, and use of specific therapy have all been shown to improve diagnostic specificity and would decrease the risk of bias introduced via misclassification. 14, 15 We therefore have referred to our cases as SLE/ likely SLE for accuracy, to reflect this methodologic limitation. Responses to the twoyear surveys were low; only 61% of SLE and 68% of OA returned questionnaires at two years, yielding limited two-year self-report data for our analysis. Patients with poor outcomes and patients with chronic diseases are less likely to respond to questionnaires, 30, 31 creating significant challenges in studying chronically ill SLE patients. This would favor patients with better outcomes returning the surveys, creating the potential for selection bias due to differential non-response. However, it is important to note that baseline characteristics were similar between those with two-year follow-up and those without. Alternatively, there may be bias introduced when patients with a chronic disease are more careful in answering medical questions than healthy controls, creating the potential for response bias. Although we matched on age, sex, procedure and presence of AVN, there may be other confounders present that we did not analyze, such as medication use or comorbidities, that could have introduced another potential source of bias. We lacked specific SLE measures of disease activity as well as SLE serologies. We had no information regarding the duration of corticosteroid therapy prior to the development of AVN, which would have been of interest. In addition, all surgeries were performed in a high-volume tertiary referral orthopedic hospital, so the results may not be generalizable, as most arthroplasties are performed in community hospitals. 32, 33 Strengths of our study include a large cohort of SLE/likely SLE patients with radiographic or pathologic validation of AVN. While previous retrospective series have reported benefits to health-related quality of life (HRQOL) and improved function for SLE patients after THA, 5,34 our series of SLE/likely SLE patients analyzes prospectively gathered data both for THA and TKA, using appropriately matched contemporaneous surgical controls undergoing the same operation.
In summary, the results of this study suggest that patients with SLE/likely SLE have marked improvements in pain and function after THA and TKA and that SLE itself is not associated with worse short-term postoperative pain or function. Although significant differences between the SLE/likely SLE THA and TKA patients were observed, outcomes between the groups were similarly excellent. This is important information to consider when counseling SLE patients contemplating arthroplasty.
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